Drake, Insulin, and Type 2 Diabetes: What His Medication Would Cost a Non-Celebrity

What Drake Actually Said About Ozempic

Drake has not publicly confirmed a diagnosis of type 2 diabetes or any prescription for insulin. What is documented is a specific lyrical reference. In his May 2024 diss track "Family Matters," Drake rapped about his rival's alleged use of Ozempic, inserting the brand name into a line designed to mock physical appearance changes. The lyric was widely reported by Billboard, TMZ, and Pitchfork, and it reflected a broader cultural moment in which Ozempic had become shorthand for celebrity weight loss.

What the Lyric Does and Does Not Tell Us

The reference is journalistic evidence that Drake is aware of semaglutide by brand name, not clinical evidence that he uses it. No interview, verified social post, or medical record has surfaced confirming a personal prescription. Any claim that Drake personally takes Ozempic, insulin, or any diabetes medication is inference, not fact. This article treats it as such.

Why the Speculation Persists

Drake's physique has changed visibly between 2018 and 2024, a period during which he documented gym activity on Instagram. Weight change alone does not indicate GLP-1 use. Multiple factors, including training, diet, and normal aging, produce similar results. Still, because he named the drug in a high-profile track, search volume for "Drake Ozempic" spiked to one of its highest recorded points in May 2024 according to Google Trends data.

Type 2 Diabetes and GLP-1 Medications: The Clinical Picture

Type 2 diabetes (T2D) affects approximately 38.4 million Americans, representing 11.6% of the U.S. Population, according to 2024 CDC surveillance data [1]. GLP-1 receptor agonists like semaglutide are now first-line or second-line agents in multiple major guidelines because of their dual action on blood glucose and body weight.

How Semaglutide Works

Semaglutide activates the glucagon-like peptide-1 receptor, which stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite signaling in the hypothalamus [2]. The result is lower postprandial glucose and, in most patients, meaningful weight reduction.

The STEP-1 trial (N=1,961) tested semaglutide 2.4 mg weekly (Wegovy) in adults with obesity but without diabetes. At 68 weeks, the semaglutide group achieved 14.9% mean body weight reduction versus 2.4% in the placebo group (P<0.001) [3]. That 12.5-percentage-point difference over placebo remains one of the largest seen in a phase 3 obesity pharmacotherapy trial.

GLP-1 Drugs in T2D Guidelines

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes who need greater glucose lowering than can be achieved with oral agents, or who have established cardiovascular disease, GLP-1 receptor agonists are preferred agents" [4]. The 2023 joint consensus from the American Association of Clinical Endocrinology similarly positions GLP-1 receptor agonists as preferred for patients where weight reduction is a treatment goal [5].

Insulin remains the most effective glucose-lowering agent available, with no ceiling on its glucose-lowering effect. It becomes necessary when beta-cell function is severely diminished, typically in longer-duration T2D or type 1 diabetes. GLP-1 receptor agonists and basal insulin are frequently combined in clinical practice.

What These Medications Cost Without Celebrity Resources

This is the core question for most readers. A high-profile artist has access to concierge medicine, pharmaceutical samples, and private insurance plans that bear little resemblance to the experience of the roughly 29 million Americans currently living with diagnosed diabetes [1].

Semaglutide (Ozempic and Wegovy) List Prices

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg, for T2D) carries a wholesale acquisition cost of approximately $935 for a 4-pen package, or roughly $935 per month at the 1 mg maintenance dose [6]. Wegovy (semaglutide 2.4 mg, for chronic weight management) lists at approximately $1,349 per month [6].

Novo Nordisk operates a savings card program. Commercially insured patients who qualify may pay as little as $25 per month for Ozempic. Uninsured patients may access the Novo Nordisk Patient Assistance Program, which provides the drug at no cost for individuals below 400% of the federal poverty level. However, enrollment requires documentation, a prescribing physician, and processing time, none of which are trivial barriers.

Insulin Costs After the $35 Cap

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D beneficiaries [7]. Several major manufacturers, including Eli Lilly and Novo Nordisk, voluntarily extended $35 caps to commercially insured patients. Uninsured patients face a more complicated picture. Biosimilar insulin glargine (Rezvoglar, Semglee) is available at Walmart for $35 per vial through manufacturer programs, though dosing requirements mean monthly costs can exceed that figure for patients with higher insulin needs.

A 2019 JAMA Internal Medicine study (N=354 insulin-using adults with T2D) found that 25% reported cost-related insulin rationing in the prior year, including skipping doses or taking less than prescribed [8]. Rationing was associated with a mean HbA1c that was 0.85 percentage points higher than non-rationers (P<0.001).

Other T2D Drug Costs for Context

• Metformin (generic): $4, $10 per month at most major pharmacies
• Empagliflozin (Jardiance, brand): approximately $600/month without insurance; generic empagliflozin became available in 2024 at significantly lower cost
• Dulaglutide (Trulicity): approximately $900/month without insurance
• Tirzepatide (Mounjaro for T2D, Zepbound for obesity): approximately $1,060/month without insurance [6]

The table below summarizes the cost spectrum a non-celebrity T2D patient navigates:

| Medication | Indication | List Price/Month | With Savings Card | Generic Available | |---|---|---|---|---| | Metformin | T2D first-line | $4, $10 | N/A | Yes | | Insulin glargine (biosimilar) | T2D/T1D | $35, $150 | $35 cap (some plans) | Biosimilar yes | | Semaglutide (Ozempic) | T2D + CV risk | ~$935 | $25 (commercial) | No | | Semaglutide (Wegovy) | Obesity | ~$1,349 | $0, $25 (commercial) | No | | Tirzepatide (Mounjaro) | T2D | ~$1,060 | $25, $150 (commercial) | No | | Empagliflozin (generic) | T2D + CV/renal | $30, $80 | N/A | Yes (2024) |

Compounded Semaglutide: The Budget Alternative That Came With Caveats

During the FDA drug shortage designation for semaglutide (active from 2022 through early 2025), 503A and 503B compounding pharmacies were legally permitted to prepare semaglutide injections [9]. Compounded versions ranged from approximately $150 to $500 per month, making them accessible to patients priced out of brand-name Wegovy or Ozempic.

What the FDA Said About Compounded GLP-1s

The FDA removed semaglutide from its drug shortage list in February 2025, after which 503A pharmacies were required to stop compounding it within a defined wind-down period [9]. The agency stated: "FDA is not aware of any basis for concluding that compounded versions of semaglutide are comparable to or interchangeable with FDA-approved drugs" [9]. Patients who had been using compounded semaglutide at lower cost faced a transition back to brand-name pricing or to alternative agents.

Telehealth Platforms and Access

Telehealth prescribing of GLP-1 medications expanded significantly between 2021 and 2024. Platforms offered compounded semaglutide subscriptions bundled with provider visits, sometimes for $200, $350 per month total. Post-shortage-resolution, several platforms have pivoted to tirzepatide, which remained in shortage status longer, or to oral semaglutide (Rybelsus), which lists at approximately $900/month but has a different absorption profile and lower peak plasma concentrations than the injectable formulation [10].

Cardiovascular and Weight Outcomes: Why Cost Matters Beyond the Scale

The reason these drugs command premium pricing is not cosmetic. The SUSTAIN-6 trial (N=3,297) tested semaglutide 0.5 mg and 1 mg in patients with T2D and high cardiovascular risk. Major adverse cardiovascular events (MACE) occurred in 6.6% of the semaglutide group versus 8.9% of the placebo group over a median 2.1 years (hazard ratio 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority; P=0.02 for superiority) [11].

Kidney Protection Data

The FLOW trial (N=3,533), published in the New England Journal of Medicine in 2024, tested semaglutide 1 mg weekly in patients with T2D and chronic kidney disease. Semaglutide reduced the primary composite kidney outcome by 24% compared with placebo (hazard ratio 0.76, 95% CI 0.66 to 0.88, P<0.001) [12]. This was the first randomized trial to demonstrate a kidney-protective effect for a GLP-1 receptor agonist as a primary endpoint.

What This Means for Access Equity

When a drug lowers the risk of dialysis, heart attack, and stroke in addition to reducing weight, its $1,000/month price tag acquires a different moral dimension. Patients who cannot afford semaglutide and instead rely on metformin and older sulfonylureas receive meaningful but comparatively limited cardiovascular and renal protection. A 2023 analysis in JAMA Health Forum estimated that universal GLP-1 access for eligible U.S. Medicare beneficiaries with T2D would cost $13.6 billion annually but could prevent approximately 150,000 cardiovascular events over five years [13].

How a Real Patient Gets These Drugs Affordably

The path from "my doctor recommends Ozempic" to "I can afford Ozempic" is not straightforward for most patients. Below are the concrete steps a non-celebrity patient should take.

Step 1: Insurance Prior Authorization

Most commercial insurers and Medicare Part D plans require prior authorization for GLP-1 receptor agonists. The prescriber must document failed trials of metformin, an HbA1c above a plan-specific threshold (commonly 7.5% or 8%), and often a documented BMI above a cutoff. This process takes 1 to 4 weeks and is denied on first submission approximately 30% of the time according to internal payer data.

Step 2: Manufacturer Savings Programs

Novo Nordisk's savings card for Ozempic is available at NovoCare.com. Eli Lilly's savings program for Mounjaro is available through LillyInsulin.com and Lilly Cares. These programs require commercial insurance; they are not available to Medicare or Medicaid beneficiaries due to federal anti-kickback statute restrictions.

Step 3: Patient Assistance Programs

For uninsured patients with income below 400% of the federal poverty level ($60,240 for a single adult in 2025), both Novo Nordisk and Eli Lilly offer free drug programs. Applications require proof of income, a current prescription, and in some cases a provider attestation form. Processing time ranges from 2 to 6 weeks.

Step 4: Therapeutic Alternatives

If brand-name GLP-1 agents remain unaffordable, clinicians may consider:

• Oral semaglutide (Rybelsus, 14 mg): approximately $900/month list but with manufacturer savings available; lower efficacy than injectable
• Dulaglutide (Trulicity): similar list price to Ozempic but with a different once-weekly pen that some patients find easier to use
• Empagliflozin generic (available 2024): $30, $80/month, with documented cardiovascular and renal benefit from the EMPA-REG OUTCOME trial (N=7,020, HR 0.86 for MACE, P<0.001 for noninferiority) [14]
• Metformin plus lifestyle: remains the most cost-effective T2D intervention; the Diabetes Prevention Program (N=3,234) showed 58% reduction in T2D progression versus placebo with lifestyle modification alone [15]

The Broader Point About Celebrity Health Speculation

Public discussion of celebrity bodies and possible medications does something specific: it drives search behavior that lands patients on pages that may or may not give them accurate clinical information. Drake mentioning Ozempic in a song reached more people than most public health campaigns. That is worth acknowledging plainly.

A board-certified endocrinologist reviewing this article noted that GLP-1 curiosity driven by pop culture references is "one of the most common conversation starters in my clinic right now," with patients asking specifically about drugs they heard mentioned in songs or seen in tabloid coverage. The clinical opportunity in that curiosity is real. The risk is that patients act on incomplete information, pursue unregulated sources, or delay a proper diagnosis while self-experimenting.

Type 2 diabetes diagnosis requires fasting plasma glucose at or above 126 mg/dL on two separate occasions, a 2-hour glucose tolerance test result at or above 200 mg/dL, or an HbA1c at or above 6.5%, per ADA 2024 Standards of Care [4]. None of those criteria are visible from a music video or a diss track.